Icosa

The present invention relates to a perfume bottle coated with a filtering film allowing protection of aroma compounds sensitive to UV-light.

The invention relates to aza-bisphosphonate dendrimers, or their pharmaceutically acceptable salts thereof, for use in the treatment and/or prevention of a disease or disorder involving bladder inflammation.

The present invention relates to a device (1) and associated computer-implemented method (100) for obtaining at least one trained machine learning model (41) configured at least to predict a risk of occurrence (42), in a predefined time interval, of at least one rare event for a patient, and to a device (2) and associated computer-implemented method (200) for predicting a risk of occurrence (42), in a predefined time interval, of at least one rare event for a patient using the obtained at least one trained machine learning model (41).

The present invention relates to a crude microbial oil of Thraustochytrid rich in docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which comprises at least 94% of triglycerides. The present invention further relates to a process for producing said crude microbial oil, as well as its uses.

The present disclosure relates to a dry implant suitable for rehydration before placement in a human or animal body.

The present invention relates to a liquid and vaporizable composition comprising: (1) a distillate of at least one cannabinoid selected from THC, CBD and their mixtures thereof wherein the distillate comprises less than 1% by weight of terpene, based on the total weight of distillate, (2) and at least one diol selected from 1,2-propanediol 1,3-propanediol, 1,3-butanediol, 1,4-butanediol, 2-methyl-1,3-propanediol, polyethylene glycol (PEG), polyethylene glycol 400 (PEG 400), and mixtures thereof. The composition is used as a medicament wherein a constant dose of cannabinoid(s) is delivered to a subject in need through a vaporizing device.

The present invention relates to branched ionizable phospholipids. In particular, this invention relates to branched ionizable phospholipids of formula (I). This invention also relates to a process for manufacturing said compounds of formula (I). This invention also relates to lipid nanoparticles obtained by formulation of the compounds of general formula (I). This invention also relates to the use of the compounds of formula (I) and of lipid nanoparticles obtained by formulation of the compounds of general formula (I).

Medical devices, including insertable/implantable medical devices, may include proteins bound to a nickel titanium surface of the medical device. In some cases, the medical device may include a protein (e.g., a fibrin-binding protein) coating a surface of the medical implant. For example, the protein may be covalently bound via a covalent ester bond directly to the nickel titanium surface of the medical device. Also described herein are methods of making and using such medical devices.

The present disclosure relates to a method of encapsulation of nanoparticles in a metal oxide matrix by spraying in which evaporation of solvent and triggering of reaction of formation of oxide matrix are successive in time.

A secondary battery includes a non-aqueous electrolyte. The non-aqueous electrolyte includes: fluoroethyl propionate, where the fluoroethyl propionate is selected from the group consisting of 2,2-difluoroethyl propanoate, 2,2,2-trifluoroethyl propionate, and a combination thereof, and based on a total mass of the non-aqueous electrolyte, a mass percentage of the fluoroethyl propionate is 5% to 65%; and ethylene carbonate (EC) and propylene carbonate (PC), where based on the total mass of the non-aqueous electrolyte, the sum of the mass percentages of the ethylene carbonate (EC) and the propylene carbonate (PC) is less than or equal to 15%.